Efficacy of two low-dose oral tylosin regimens in controlling the relapse of diarrhea in dogs with tylosin-responsive diarrhea: a prospective,single-blinded,two-arm parallel,clinical field trial

Background

Despite its wide acceptance as a treatment for canine chronic enteropathies, the macrolide antibiotic tylosin lacks official oral dosage recommendations. Not even textbooks share consensus about the dose; daily recommendations vary from 25 to 80 mg/kg and dosing intervals from one to three times daily.The objective of this prospective, single-blinded, two-arm parallel, clinical field trial was to determine whether doses of 5 mg/kg or 15 mg/kg tylosin administered orally once daily for seven days would have a similar effect on fecal consistency in diarrhea relapses to that of a 25 mg/kg dose of tylosin administered once daily for seven days, a dosage that has proved effective in controlling canine tylosin-responsive diarrhea (TRD). A further objective was to compare the efficacy of the 5 mg/kg and 15 mg/kg tylosin dosages. Fifteen client-owned dogs diagnosed with TRD that had responded to a dose of 25 mg/kg tylosin once daily for seven days were enrolled in the study. After a relapse of diarrhea the dogs were allocated into two groups receiving tylosin orally in doses of either 5 mg/kg or 15 mg/kg once daily for seven days. The owners were blinded to the dosage. The elimination of diarrhea was the main criterion in assessing treatment success. The mean fecal consistency score of the last three treatment days for all dosages, including 25 mg/kg, as evaluated by the owners according to a standardized fecal scoring system, served as the primary outcome measures.

Results

All eight dogs responded to the 5 mg/kg dose, and six of seven dogs responded to the 15 mg/kg dose. The mean fecal consistency scores at the 25 mg/kg tylosin dosage were no significantly different from scores at the 5 mg/kg or 15 mg/kg tylosin dosages (P = 0.672, P = 0.345).

Conclusions

Interestingly, 14/15 (93%) of the dogs responding to a dose of 25 mg/kg tylosin once daily for seven days also responded to the lower dosages at diarrhea relapse. The data indicate that a suitable dose of tylosin for treating diarrhea relapse in canine TRD could be as low as 5 mg/kg once daily for seven days.     

Fluoxetine combined with clorazepate dipotassium and behaviour modification for treatment of anxiety-related disorders in dogs

The effectiveness of clorazepate dipotassium combined with fluoxetine and a behaviour modification programme for the treatment of anxiety disorders in dogs was investigated. Forty dogs with anxiety disorders were initially enrolled and 36 dogs completed the trial. Dogs were classified into two behavioural categories (anxious dogs with aggression and anxious dogs without aggression) according to their presenting complaints, and were also subdivided into males, females, juveniles and adults. The dog owners were provided with a behaviour modification plan for their dogs to be commenced in the first week of therapy. Clorazepate dipotassium was administered PO at 1.0 mg/kg every 24 h for 4 weeks, and fluoxetine was administered PO at 1.0 mg/kg every 24 h for 10 weeks. Therapy with both drugs was initiated simultaneously. Improvement was reported in 25/36 dogs. Significant differences in treatment effects were observed between anxious dogs with aggression and anxious dogs without aggression (P < 0.05). Positive correlations between owner compliance with the treatment plan and reported improvement achieved during three periods of study were also noted.     

Investigation of the clinical efficacy of 0.2% topical stannous fluoride for the treatment of canine superficial pyoderma: a prospective,randomized, double‐blinded,placebo‐controlled trial

Stannous fluoride (SF) is an antibacterial compound that has been successfully used to treat gingivitis in people and dogs, and cutaneous bacterial infections in horses. The purpose of this prospective, double‐blinded, placebo‐controlled clinical trial was to investigate the efficacy of 0.2% SF spray (BacDerm^®; Emerald 3 Enterprises Inc., Camdenton, MO, USA) for the treatment of canine superficial pyoderma. Twenty‐six privately owned dogs with bacterial skin infections diagnosed on clinical signs, cytology and aerobic culture were enrolled. Dogs were randomly assigned to vehicle only or active ingredient treatment groups. The product was applied topically to affected areas once daily for 28 days, with assessments at days 0, 14, 28 and 42. Clinical and cytological evaluations were performed by the same investigators at each visit. Owners scored the improvement of hair coat, odour, pruritus and overall improvement at each recheck. Linear mixed models showed significant effects of treatment (P < 0.0001) and time (P = 0.0037) for investigator’s scores, and a significant time effect for owners’ haircoat (P = 0.0077) and odour (P = 0.0170) improvement scores. Dogs in both placebo and SF groups showed some improvement over time, and the investigator’s scores on days 0 and 28 were not significantly different between groups for both (t‐test P > 0.05). Spearman’s rho correlation coefficients revealed a significant negative correlation between investigator’s scores and all categories of owners’ assessment scores in dogs of both groups. Although some dogs improved on SF, this study does not support the use of 0.2% SF as sole therapy for canine superficial pyoderma.     

The use of altrenogest to control aggression in a male Grant's Zebra (Equus burchelli boehmi).

A male Grant's Zebra (Equus burchelli boehmi) housed with two mares at the Indianapolis Zoo had a 9-yr history of intermittent aggressive behavior toward mares and other animals. Periods of separation allowed the mares time to heal after sustaining superficial bite wounds. On 26 March 2003, the male (890293) was started on altrenogest at a dosage of 19.8 mg orally once daily to allow reintroduction. The dosage was doubled (40 mg once a day) because of a perceived lack of response. Reintroduction to the mares occurred on 17 May 2003 with no signs of aggression noted. Treatment was reduced to 19.8 mg orally once a day and then discontinued. Altrenogest was restarted at 39.5 mg orally once a day because of the planned introduction of a new mare. There have been no major aggressive displays at this dosage of altrenogest and the dosage has recently been reduced following successful introduction of a new mare.     

Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease

AIM: To evaluate the efficacy and tolerance of an extract of green-lipped mussel (GLME) in the management of mild-to-moderate degenerative joint disease (DJD) in dogs. METHODS: Eighty-one dogs presumptively diagnosed with DJD were treated orally daily with either GLME or a placebo for 56 days, in a double-blind, placebo-controlled study. In an uncontrolled open-label extension to the study, all dogs were treated with GLME for an additional 56 days (from Days 57-112). Clinical signs were subjectively scored by the owners, and findings of detailed musculoskeletal examinations were scored by one veterinarian. Efficacy was assessed from a qualitative comparison of the proportion of dogs with improved clinical signs, and a quantitative comparison of the scores of the musculoskeletal examinations, between groups. Haematological and biochemical analyses and reports by owners of possible adverse drug reactions were used to screen for evidence of toxicity. RESULTS: There was close agreement between assessments by the veterinarian and owners. The clinical signs of DJD in both GLME-treated and placebo groups improved significantly over baseline by Day 28; this improvement continued over the entire course of the study. There were no significant differences between groups on Day 28. On Day 56, a higher proportion of dogs in the GLME-treated group had improved clinical signs (p=0.018), and GLME-treated dogs had marginally better (p=0.053) musculoskeletal scores than dogs in the placebo group. The differences between the groups were no longer apparent by Day 112, by which time the former placebo group had been receiving GLME for 56 days in the open-label phase of the study. The proportion of dogs in the former placebo group that had improved by Day 112 (29/32; 91%) was significantly greater (p=0.012) than the proportion improved at Day 56 (15/37; 41%). No signs of toxicity were apparent. CONCLUSIONS AND CLINICAL RELEVANCE: GLME had a beneficial effect on the clinical signs of dogs presumptively diagnosed with mild-to-moderate DJD. Long-term therapy may be required before improvement is apparent.     

Behavior of hearing or vision impaired and normal hearing and vision dogs (Canis lupis familiaris): Not the same,but not that different

The article compared behavioral characteristics of dogs (Canis lupis familiaris) labeled as hearing and/or vision impaired by their owners with cohort dogs labeled as having normal hearing and vision (NHV) by their owners. The Canine Behavioral Assessment and Research Questionnaire, developed by Hsu and Serpell (2003), was used to survey owners. Four hundred sixty-one dog owners completed the online survey, with 183 of these being owners of hearing and/or vision impaired (HVI) dogs. Data analysis revealed that HVI dogs were reported by owners to show less aggression, less excitement, and were less likely to engage in behaviors, such as chasing of rabbits and rolling in feces than their normally hearing/seeing (NHV) cohorts. HVI dogs, however, were reported to be more likely to chew inappropriate objects, consume feces, bark excessively, and engage in greater licking behavior. When owners were surveyed about the type of training method used, owners of HVI dogs were found to be more likely to use hand signs, physical prompts, or combination of these training methods. Owners of NHV dogs reported being more likely than owners of HVI dogs to use gestures or report no formal training with their dogs. The data provide evidence that HVI dogs are as trainable as NHV dogs, can make excellent pets, and show behavior that is well within the parameters of NHV dog behavior. Still, because of their sensory limitations, specialized training methods and adaptations should be implemented with these dogs. This may limit HVI dogs to owners who are motivated, understand the sensory deficits, and are willing to engage in the modified training.     

Oral vitamin A as an adjunct treatment for canine sebaceous adenitis

Medical records of dogs with sebaceous adenitis diagnosed by histopathology over an 18-year period were reviewed. From a total of 40 cases, 24 were treated with oral vitamin A. Dogs ranged from 9 months to 12 years of age at the time of disease onset. Purebred as well as mixed-breed dogs were affected. Akitas represented approximately one-third of the affected population. No sex predilections were observed. Vitamin A was administered for a minimum of 1 month. Doses varied from 380 to 2667 IU/kg/day, with a mean of 1037 IU/kg/day. Two dogs received oral vitamin A exclusively. Concurrent treatments included systemic antibiotics, systemic antifungal medications, fatty acid supplementation and various topical treatments. Of 24 dogs treated with vitamin A, three were lost to follow-up. Twelve owners were satisfied with the overall appearance of their dogs, reporting ≥25% improvement in clinical signs, including level of pruritus, amount of scale, alopecia and overall coat quality, compared with pretreatment appearance. Three owners observed adequate initial improvement, with regression to pretreatment state within 6 months of starting treatment. Two owners reported 25-50% improvement in clinical signs while on oral vitamin A supplementation; however, changes were attributed to concurrent topical treatment. Six owners reported no improvement and discontinued oral administration of vitamin A within 7 months. No correlations could be made between vitamin A dosage and response to treatment; prognoses could not be made based on clinical and histopathological findings.     

Effect of tylosin on dogs with suspected tylosin-responsive diarrhea: a placebo-controlled,randomized, double-blinded,prospective clinical trial

Background

The macrolid antibiotic tylosin has been widely used to treat canine chronic diarrhea, although its efficacy is based on anecdotal reports and experimental studies in dogs and not on strong scientific evidence. The term tylosin-responsive diarrhea (TRD) refers to diarrheal disorders responding to tylosin therapy within a few days. In TRD, the stool remains normal as long as tylosin treatment continues, but diarrhea reappears in many dogs within weeks after discontinuation. The aim of our trial was to assess the effect of tylosin on fecal consistency compared with a placebo treatment in dogs with suspected TRD and additionally to establish whether tylosin in dogs with recurrent diarrhea is as effective as empirical studies and anecdotal reports suggest.

Methods

Subjects comprised 71 client-owned dogs that, according to the owners, had previously been treated successfully with tylosin due to recurrent diarrhea of unknown etiology. At the initial examination, where there were no signs of diarrhea, the dogs were randomly assigned in a 2:1 ratio to a tylosin or placebo group. During a two-month follow-up the owners evaluated the fecal consistency according to previously published guidelines. When diarrhea recurred, either tylosin (25 mg/kg q 24 h, 7 days) or placebo treatment was initiated orally. Treatment outcome was evaluated as the mean of fecal consistency scores assigned during the last three days of the treatment period. To test for differences between the tylosin and placebo group in the proportion of responders, Pearson''s Chi-squared test and Fisher''s exact test were applied.

Results

Sixty-one dogs met the selection criteria and were followed for two months. During the follow-up 27 dogs developed diarrhea and either tylosin or placebo treatment was started. The proportion of dogs with normal fecal consistency at the end of treatment was 85% (17/20) in the tylosin group and 29% (2/7) in the placebo group (Pearson''s Chi-squared test p = 0.0049 and Fisher''s exact test two-sided, p = 0.0114).

Conclusions

Our findings indicate that tylosin is effective in treating recurrent diarrhea in dogs. The dose of 25 mg/kg once daily appears sufficient. No changes specific to TRD were detected in the examinations.     

Video analysis of dogs suffering from anxiety when left home alone and treated with clomipramine

This study sought to film dogs with separation anxiety when left home alone while undergoing treatment with clomipramine and to compile objective information on behaviors exhibited. Twenty-three dogs ranging in age from 5 months to 9 years (mean, 3 ± 2 years) were included. The dogs were filmed when left home alone for variable periods ranging from 22 to 90 minutes after owner departure. Owners were required to film their dog on 5 occasions. Film 1 served to confirm a diagnosis of separation anxiety. Medication (clomipramine) was prescribed to all dogs. The owners were then asked to film the dogs on days 7, 14, 28, and 56 of the pharmacological treatment, but only 3 repetitions (days 0, 7, and 14) were used for statistical analysis. The initial dosage of clomipramine was 1 mg/kg twice daily for the first week and was then increased to 2 mg/kg twice daily. Any differences in behavior that occurred after clomipramine administration were evaluated using Friedman and Wilcoxon nonparametric tests. A significant beneficial effect of the dosage of 1 mg/kg every 12 hours of clomipramine in increasing passive behavior and reducing locomotion (pacing), scratching, and whining was demonstrated. A beneficial effect of 2 mg/kg every 12 hours in reducing vocalizations (barking and whining) and further increasing time spent in a passive state (resting or sleeping) was also shown. Some signs of separation anxiety may have improved as a consequence of the basic recommendations provided to the dog owners. This study not only confirms the importance of filming dogs home alone for the diagnosis of separation anxiety but also emphasizes the advantages of filming during the treatment of separation anxiety. Clinical effects can be seen as early as 1 week after starting the medication (clomipramine).     

The effect of a spot-on formulation containing polyunsaturated fatty acids and essential oils on dogs with atopic dermatitis

Recent studies have shown that immunological aberrations and epidermal barrier defects could be important in the pathogenesis of canine atopic dermatitis (CAD) and that oral polyunsaturated fatty acids (PUFAs) might influence the epidermal barrier. The aim of this study was to evaluate the effects of a spot-on formulation containing PUFAs and essential oils on pruritus and lesions caused by CAD. Forty-eight privately owned dogs of different breeds, ages and genders diagnosed with atopic dermatitis were included in a randomized, double-blinded, placebo-controlled, multicentre clinical trial. Dogs were treated with a spot-on formulation containing PUFAs and essential oils or placebo on the dorsal neck once weekly for 8 weeks. Before and after the study, CAD extent and severity index-03 (CADESI-03) and pruritus scores were determined by veterinarians and owners, respectively.There was significantly more improvement in CADESI-03 and pruritus scores in the treatment group than in the placebo group (P = 0.011 and P = 0.036, respectively). Additionally, more dogs improved by at least 50% in CADESI-03 and pruritus scores in the treatment group than in the placebo group (P = 0.008 and P = 0.070, respectively). No adverse reactions were observed. The topical preparation containing PUFAs and essential oils was a safe treatment and beneficial in ameliorating the clinical signs of CAD.     

Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial

The efficacy and field safety of marbofloxacin (Zeniquin) for the treatment of superficial and deep bacterial pyoderma were evaluated. Seventy‐two dogs were treated with 2.75 mg kg^?1 of marbofloxacin orally once daily for 21 or 28 days. Sixty‐two dogs (86%) had superficial pyoderma and 10 (14%) had deep pyoderma. A history of prior pyoderma was reported in 39/72 dogs. Pretreatment aerobic bacteriologic cultures of skin lesions were performed in 47 cases and the predominant pathogen isolated was Staphylococcus intermedius. Treatment was successful in 62/72 (86.1%) dogs, improvement was noted in 6/72 (8.3%) dogs and treatment failed in 4/72 (5.6%) dogs. Adverse effects associated with treatment included listlessness, anorexia, vomiting, soft stool, flatulence and polydipsia; these adverse effects were seen in only 6/81 dogs. Marbofloxacin was safe and effective for the treatment of superficial and deep pyoderma in dogs at the dosage used in this study.     

Effects of preadoption counseling on the prevention of separation anxiety in newly adopted shelter dogs

Separation anxiety is one of the more prevalent and difficult to treat behavior problems in dogs. The associated behaviors can be undesirable to dog owners and damage the human animal bond, leading to relinquishment or return to an animal shelter. Due to the high prevalence of separation related problems in recently adopted shelter dogs, shelter staff hold a critical role in advising and educating owners on how to prevent separation anxiety post-adoption. The aim of this study was to propose a form of that preventive counseling as a means of preventing the development of separation anxiety in recently adopted shelter dogs. The efficacy of preadoption counseling in the education and prevention of separation anxiety problems was tested in a prospective, randomized, parallel-group study. Participants included 133 new owners of dogs 6 months of age and older. At the time of adoption, sixty-six of these owners were randomly selected to receive five minutes of counseling on the prevention of separation anxiety, while the remaining sixty-seven owners served as the controls. A follow-up survey regarding the signs associated with separation anxiety and other potentially related behaviors was conducted one month post adoption. Results showed that 19 owners reported their dogs as having separation anxiety. There was no significant effect of adoption counseling on the prevention of separation anxiety. Owners in both groups were equally as likely to perform most of the recommendations given during counseling. Dogs that were reported to have separation anxiety were significantly more likely than dogs without reported separation anxiety to show nervous or panicked behavior as the owner prepared to leave (P = 0.0001) and were more likely to be reported as being “needy” (P = 0.031). Having another dog in the home was not protective against the development of separation anxiety. Owners in the counseling group were more likely than those in the control group to put food inside a toy at the time of leaving the dog home alone (P = 0.0001), suggesting the counseling recommendations were indeed followed by the owners. Owner compliance supports the idea that counseling is a useful tool for owners. Separation anxiety is a disorder whose course may be difficult to alter in recently adopted shelter dogs using only basic, interventional information. Brief counseling and a toy do not effectively prevent the occurrence of this complex behavioral condition. Further investigation should be done to find more specific, effective prevention tools for owners to use in the home to minimize the development of separation anxiety and shelter should be prepared to provide interventional resources to owners whose dogs develop separation anxiety despite these efforts.     

Long-term use of cyclosporine in the treatment of canine atopic dermatitis

This retrospective study of 51 dogs with atopic dermatitis (AD) treated with cyclosporine (CsA) for a minimum of 6 months assessed the frequency of dosing and the need for continual treatment to control clinical signs. The study evaluated both medical records and information supplied by the owners in the form of written questionnaires and telephone follow-up. Laboratory parameters, possible adverse effects and owner satisfaction were assessed. The dose of CsA was 5 mg/kg orally per day and dogs received CsA for 6-30 months. At the conclusion of the study period, 28 dogs (55%) needed ongoing CsA to control clinical signs of AD: 8 (15%) received CsA 2-3 days per week, 10 (20%) 4-5 days per week, and 10 (20%) daily. CsA was discontinued in 23 dogs (45%) after 6-24 months due to either a limited response (22%) or after achieving a clinical response (24%). The results suggest that some dogs with AD treated with CsA may not require daily or even ongoing treatment to control clinical signs. Laboratory abnormalities were detected in 13 dogs (25%) during their CsA treatment. Two dogs developed oral growths and three developed hirsuitism. Forty owners (78%) reported no adverse events in their dogs during the treatment period. Thirty-six owners (71%) were satisfied with CsA as treatment for their atopic dog.     

Use of memantine in treatment of canine compulsive disorders

Medication plays an important role in the treatment of canine compulsive disorders (CCD). Not all cases can be managed with the current medications, and new pharmacological options are needed. This case series assesses the efficacy of the NMDA receptor blocker memantine as a possible new treatment option for CCD. Thirteen dogs with different manifestations of CCD were enrolled in the study, and data from 11 dogs were available for analysis. A behavioral and clinical history was obtained for each dog. Further medical tests were performed if deemed necessary.The main presenting complaints in the included cases were light/shadow chasing, spinning/circling, and tail chasing. All dogs were either treated with memantine alone or memantine was added to ongoing fluoxetine treatment. All owners of dogs included in the study were provided with a specific behavior modification plan in addition to the pharmacological treatment. Memantine was administered orally twice a day at a starting dose of 0.3-0.5 mg/kg. The dose was increased over time if necessary, and side effects permitting, to a dose not higher than 1 mg/kg. The owners were asked to use a clinical global impression scale (CGI) on a daily basis to assess the severity of their dog's compulsive behaviors. This score was obtained daily for up to 4 consecutive weeks, and average weekly scores were calculated.Seven (64%) of the dogs included in the study showed a reduction in the severity of CCD, with CGI scores reduced by the second week of treatment. Only 1 out of 11 dogs showed a side effect (increased frequency of urination) that was potentially related to the medication. The results suggest that memantine may be an effective, well-tolerated option for the treatment of CCD either as a sole treatment or as an add-on to fluoxetine. Further studies are needed to investigate the efficacy of memantine in the treatment of CCD.     

An owner survey of toys,activities, and behavior problems in indoor cats

The objective of this study was to survey the owners regarding the frequency and duration of their daily interactions with their indoor cats, the provision of toys and activities by the cat owners, and the prevalence of 6 selected behavior problems (aggression to owner, aggression to visitors, periuria, inappropriate defecation, inter-household cat aggression, and intercat aggression to outdoor cats). The sample population was 277 clients from 5 veterinary practices who presented their domestic cat for anything except a behavior problem. The average number of toys and activities reported by owners per cat was 7, and the most common toys/activities used by owners in this survey were furry mice (64%), catnip toys (62%), and balls with bells (62%). A total of 78% of the owners reported that they leave the cat's toy(s) available all the time. All owners reported playing with their cat, whereas most owners (64%) played with their cat more than 2 times per day and reported play bout durations of 5 (33%) or 10 minutes (25%). Owners who reported play bout time of 5 minutes or more reported fewer behavioral problems than those with play bouts of 1 minute (P < 0.05). A total of 61% of the owners reported that their cat engaged in 1 or more of the 6 selected behavior problem(s), but only 54% of the owners who reported behavior problems in their cats reported that they had talked to their veterinarian about the problem. The 2 most frequently reported behavior problems were aggression to the owners (36%) and periuria (24%). Female cats were 50% less likely to be reported to have 1 or more behavior problems than males despite an equal sex distribution in the survey population (P < 0.05). The relationship between individual behavior problems and individual toys and activities was evaluated by use of a logistic stepwise regression. These findings are discussed as they relate to the understanding of behavioral needs of indoor-housed cats and the potential role of environmental enrichment in the home setting.     

The Use of Megestrol Acetate in Some Feline Dermatological Problems

Twenty-one cats were treated with megestrol acetate because they were showing clinical signs associated with one of the following problems: eosinophilic ulcer, eosinophilic plaque, neurodermatitis, endocrine alopecia and miliary dermatitis. The dosage schedule was 5 mg orally per day per cat for seven days, then 5 mg every three days for 21 days.

In all cats, we noted a good improvement of the lesions as soon as treatment was started. In 25% of the patients, one treatment schedule was sufficient to control the skin disease for at least 18 months. In the remaining 75%, two treatment schedules and/or a maintenance dosage had to be established.

Side effects encountered were increased appetite, personality changes and depression.

     

Corticosteroid (methylprednisolone sodium succinate) pulse therapy in five dogs with autoimmune skin disease

Corticosteroid pulse therapy is the parenteral administration of suprapharmacologic doses of methylprednisolone sodium succinate for short periods. Five dogs diagnosed as having autoimmune skin disease were treated, using pulse therapy, with subsequent dramatic and rapid improvement of skin lesions. The dogs had no adverse clinical signs attributable to the treatment. All dogs had a relapse of clinical signs after a maintenance protocol (0.5 mg/kg, q 48 h) of orally administered prednisone was started. Skin lesions on 4 of 5 dogs eventually were controlled by prednisone, azathioprine, or gold therapy.     

Alleviative effects of gamma-aminobutyric acid (GABA) on behavioral abnormalities in aged dogs

gamma-aminobutyric acid (GABA, 30 mg/kg) was administered to aged dogs with recent history of veterinary clinic visits (mean age: 15.3 years old) once daily for 2 weeks by mixing with food. Their owners subjectively evaluated the effects of GABA on behavioral signs often associated with aging in the dogs. Improvement in some of behavioral signs was notable without any observable adverse effects. Dogs administered with GABA tended to exhibit improvement in emotional states and signs may be caused by neurovegetable dysfunction, though effects on cognitive dysfunction syndrome were not always observed. Thus, GABA administration may be one of the effective means of improving the quality of life of aged dogs.     

The impact of COVID-19 on access to canine integrative medical care in Michigan,USA, and Ontario and British Columbia,Canada

ObjectiveTo determine the effects of the COVID-19 associated restrictions on the ability of owners in Michigan (MI), USA versus Ontario (ON) and British Columbia (BC), Canada, to obtain care for their chronically painful dogs.Study designCross-sectional survey.PopulationA total of 90 owners met the inclusion criteria for the study.MethodsAn anonymous electronic survey was distributed to owners at four veterinary integrative medicine (IM) clinics during July and August 2020. Two clinics in MI and one each in ON and BC were recruited. Owners were asked about availability of IM care preceding and during COVID-19 restrictions and their opinions of the impact of COVID-19 on their dog’s health. The survey asked where owners sought care for their dogs, types of chronic conditions treated, therapeutic modalities used, and if owners had a medical background. Comparisons were made within and between groups. Thematic analysis, Fisher’s exact test, chi-square analyses, McNemar’s and Wilcoxon signed-rank tests for paired comparisons were performed (p < 0.05).ResultsDuring COVID-19 restrictions, access to IM care was better for dogs in ON and BC than in MI (p < 0.001). The negative effect of the pandemic restrictions to IM care on quality of life was perceived greater by owners in MI than those in ON and BC (p < 0.001). The owners’ medical backgrounds had no effect on attempts to access care during this time (p = 0.76).Conclusions and clinical relevanceThe results suggest that a widespread disease in humans had an adverse impact on animal welfare. Providers of veterinary care should use this experience to establish protocols to ensure continuity of care for chronically painful animals in the event of a similar situation in the future.     

Effect of Supplementation With Omega-3 Fatty Acids,Magnesium, and Zinc on Canine Behavioral Disorders: Results of a Pilot Study

Recent discoveries have shown that the chances of a dog developing a behavioral disorder may depend upon a number of factors including nutrition. The current pilot study was designed to provide an assessment of the efficacy of a dietary supplement containing omega-3 fatty acids, magnesium, and zinc on some common behavioral disorders in a population of Iranian domestic dogs. In total, 48 dogs including 6 dogs without any behavior disorder (control group) and 42 dogs with at least 1 common behavioral disorder, namely excessive activity, inappropriate elimination, fearfulness, destructiveness, and aggression toward unfamiliar people and dogs (test group), were given daily oral dose of gelatin capsules of fish oil supplements containing 330 mg eicosapentaenoic acid and 480 mg docosahexaenoic acid. Moreover, all dogs received 12-15 mg/kg of magnesium citrate and 5 mg/kg of zinc sulfate. Data were obtained using a questionnaire that dog owners were invited to fill out 2 times before (Days 0 and 42) and 2 times after the supplement treatment period (Days 84 and 126). The questionnaire asked owners whether their dog had exhibited any of the 6 common behavioral disorders on a 5-point Likert-like scale ranging from 0 (never or very rarely) to 4 (very often). The results showed no significant changes for any of the evaluated behavior disorders scale in the control group. In dogs with behavior disorders, results showed a significant reduction in the median score for the severity of fearfulness (P?=?.0083), destructiveness (P?=?.002), and inappropriate elimination (P < .001). In addition, there were no significant differences in the median score for the severity of excessive activity (P = .162), aggression toward dogs (P = .281), and aggression toward unfamiliar people (P = .09) during the course of the study. Results of the study reported here support the hypothesis that a combination of omega-3 fatty acids, magnesium, and zinc may improve some of the behavioral disorders.